中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丙型肝炎疫苗研究的新理念、挑战与策略

贾战生 马力 韦三华 姚志强

贾战生, 马力, 韦三华, 姚志强. 丙型肝炎疫苗研究的新理念、挑战与策略[J]. 临床肝胆病杂志, 2011, 27(1): 8-14.
引用本文: 贾战生, 马力, 韦三华, 姚志强. 丙型肝炎疫苗研究的新理念、挑战与策略[J]. 临床肝胆病杂志, 2011, 27(1): 8-14.
Jia ZhanSheng, Ma Li, Wei SanHua, Yao ZhiQiang. New ideas, challenges and strategies about research on hepatitis C vaccine[J]. J Clin Hepatol, 2011, 27(1): 8-14.
Citation: Jia ZhanSheng, Ma Li, Wei SanHua, Yao ZhiQiang. New ideas, challenges and strategies about research on hepatitis C vaccine[J]. J Clin Hepatol, 2011, 27(1): 8-14.

丙型肝炎疫苗研究的新理念、挑战与策略

详细信息
  • 中图分类号: R392

New ideas, challenges and strategies about research on hepatitis C vaccine

  • 摘要:

    丙型肝炎病毒(HCV)感染是引起慢性肝病的主要原因之一,严重危害人类健康,目前抗病毒治疗的标准方案为聚乙二醇干扰素α(PEG-IFN-α)联合利巴韦林,其有效率仅为50%70%,且疫苗研究进展缓慢,已成为严峻的公共卫生问题。近10多年来,对HCV感染发病机制、保护性免疫应答和病毒持续感染机制的认识取得了很大进展,中和抗体以及CD4+和CD8+T细胞在内的强烈的T细胞免疫应答已被证明与HCV的清除相关,这将是研制丙型肝炎疫苗的希望所在。当前HCV疫苗的研究主要集中在多肽疫苗、核酸疫苗、病毒载体疫苗、重组多表位疫苗、以抗原递呈细胞为载体的树突状细胞(DC)疫苗等,已有多种疫苗正在研制并进行进入临床试验前的测试。我们结合多年来对HCV的研究基础,通过与国内外同行交流,提出变"单纯预防"为"防治结合,以诱导持续免疫应答和维持病毒抑制状态为基本目标"的HCV疫苗研究新理念,发展以诱导细胞免疫为主的预防和治疗性疫苗,尤其是既能在体内有效激发HCV特异性细胞毒性T淋巴细胞(CTL)反应,又能维持CD4+记忆T细胞功能的治疗性细胞疫苗。本文综述关于HCV保护性免疫应答及持续感染的...

     

  • [1]Shepared CW, Finelli L, Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancent Infect Dis, 2005, 5:558-567.
    [2]Zeuzem S, Poordad F.Pegylated-interferon plus ribavirin therapy in the treatment of CHC:individualization of treatment duration according to on-treatment virologic response[J].Curr Med Res Opin, 2010, 26 (7) :1733-1743.
    [3]Yu CI, Chiang BL.A new insight into hepatitis C vaccine development[J].J Biomed Biotechnol, 2010, 2010:548280.Epub 2010 Jun 13.
    [4]Stoll-Keller F, Barth H, Fafi-Kremer S, et al.Development of hepatitis C virus vaccines:challenges and progress[J].Expert Rev Vaccines, 2009, 8 (3) :333-345.
    [5]Law M, Maruyama T, Lewis J, et al.Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge[J].Nature Medicine, 2008, 14 (1) :25-27.
    [6]Forns X, Payette PJ, Ma X, et al.Vaccination of ch-impanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV[J].Hepatology, 2000, 32 (3) :618-625.
    [7]Dahari H, Feinstone SM, Major ME.Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins[J].Gastroenterology, 2010, 139 (3) :965-974.
    [8]Frey SE, Houghton M, Coates S, et al.Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults[J].Vaccine, 2010, 28 (38) :6367-6373.
    [9]Bowen DG, Walker CM.Adaptive immune responses in acute and chronic hepatitis C virus infection[J].Nature, 2005, 436 (7053) :946-952.
    [10]Thimme R, Bukh J, Spangenberg HC, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J].Proc Natl Acad Sci U S A, 2002, 99 (24) :15661-15668.
    [11]Dazert E, Neumann-Haefelin C, Bressanelli S, et al.Loss of viral fitness and cross-recognition by CD8+T cells limit HCV escape from a protective HLA-B27-restricted human immune response[J].J Clin Investi, 2009, 119 (2) :376-386.
    [12]Smyk-Pearson S, Tester IA, Klarquist J, et al.Spontaneous recovery in acute human hepatitis C virus infection:functional T-cell thresholds and relative importance of CD4 help[J].J Virol, 2008, 8 (24) :1827-1837.
    [13] Semmo N, Day CL, Ward SM, et al.Preferential loss of IL-2-secreting CD4+T helper cells in chronic HCV infection[J].Hepatology, 2005, 41 (5) :1019-1028.
    [14]Shoukry NH, Cawthon AG, Walker CM.Cell-mediated immunity and the outcome of hepatitis C virus infection[J].Annu Revi Microbiol, 2004, 58:391-424.
    [15]Urbani S, Amadei B, Fisicaro P, et al.Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviralmemory CD8 responses[J].Hepatology, 2006, 44 (1) :126-139.
    [16]Stamataki Z, Grove J, Balfe P, et al.Hepatitis C virus entry and neutralization[J].Clin Liver Dis, 2008, 12 (3) :693-712.
    [17]Bustin LB, Rice CM.Flying under the radar:the im-munobiology of hepatitis C[J].Annu Rev Immunol, 2007, 25:71-99.
    [18]Limmer A, Ohl J, Kurts C, et al.Efficient presentation of exogenous antigen by liver endothelial cells to CD8+T cells results in antigen-specific T-cell Tolerance[J].Nat Med, 2000, 6:1348-1354.
    [19]Racanelli V, Rehermann B.The liver as an immunological organ[J].Hepatology, 2006, 43 (2 Suppl 1) :s54-62.
    [20]GM Lauer, E Barnes, M Lucas, et al.High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection[J].Gastroenterology, 2004, 127 (3) :924-936.
    [21]Firbas C, Boehm T, Buerger V, et al.Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine[J].Vaccine, 2010, 28 (12) :2397-2407.
    [22]Yutani S, Komatsu N, Shichijo S, et al.Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-J Clini Hepatol, January 2011, Vol.27, No.1class I-A alleles[J].Cancer Science, 2009, 100 (10) :1935-1942.
    [23]Yutani S, Yamada A, Yoshida K, et al.Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy[J].Vaccine, 2007, 25 (42) :7429-7435.
    [24]Yu H, Huang H, Xiang J, et al.Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3[J].J Gen Virol, 2006, (87) :1-10.
    [25]Gao M, Wang HP, Wang YN, et al.HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4 (+) Th1 cell responses in vivo[J].Vaccine, 2006, 24 (26) :5491-5497.
    [26]BacardíD, Amador-Ca-izares Y, Cosme K.Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus[J].Hum Exp Toxicol, 2009, 28 (8) :479-491.
    [27]冯志华, 周永兴, 焦成松, 等.Th1类细胞因子对pHCV-C重组体诱生免疫应答的增强作用[J].中国病毒学杂志, 2001, 16 (2) :101-104.
    [28]Fournillier A, Gerossier E, Evlashev A, et al.An ac-celerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses[J].Vaccine, 2007, 25 (42) :7339-7353.
    [29]Habersetzer F, Zarski JP, Leroy V, et al.A novel vectori-zed HCV therapeutic vaccine (TG4040) :results of a phase I study in naive patients chronically infected by HCV in Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver (EASL'09) [R].Copenhagen, Denmark, April 2009.
    [30]Larsson M.The dendritic cell:the immune system's adjuvant--a strategy to develop a HCV vaccine?[J].Gastroenterology, 2006, 130 (2) :603-606.
    [31]Koido S, Tanaka Y, Tajiri H, et al.Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells[J].Vaccine, 2007, 25 (14) :2610-2619.
    [32]Anderson MJ, Shafer-Weaver K, Greenberg NM, et al.Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer[J].J Immunol, 2007, 178 (3) :1268-1276.
    [33]Vietheer PT, Boo I, Drummer HE, et al.Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies[J].Antivir Ther, 2007, 12 (4) :477-487.
    [34]Cheong WS, Drummer HE, Netter HJ.Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix[J].J Virol Methods, 2009, 158 (1-2) :35-40.
    [35]Wei SH, Yin W, An QX, et al.A novel HCV vaccine approach using recombinant BCG expressing multi-epitope antigen[J].Archieve of viology, 2008, 153 (6) :1021-1029.
    [36]郝春秋, 冯志华, 贾战生, 等.复制缺陷型HCV C基因腺病毒表达载体的构建包装及鉴定[J].世界华人消化杂志, 2003, 11 (2) :144-147.
    [37] 周云, 李端, 陈琳, 等.HCV多CTL表位树突状细胞疫苗的构建及体外刺激T细胞反应[J].临床肝胆病杂志, 2011, 27 (1) :40-44.
    [38]Li W, Li J, Tyrrell DL, et al.Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of pro-inflammatory cytokines and normal T-cell stimulation capabilities[J].J Gen Virol, 2006, 87 (Pt 1) :61-72.
    [39]Firbas C, Jilma B, Tauber E, et al.Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine:a randomized, placebo controlled trial for dose optimization in 128 healthy subjects[J].Vaccine, 2006, 24 (20) :4343-4353.
    [40]Vider-Shalit T, Raffaeli S, Louzoun Y.Virus-epitope vaccine design:informatic matching the HLA-I polymorphism to the virus genome[J].Mol Immunol, 2007, 44 (6) :1253-1261.
    [41]Day CL, Lauer GM, Robbins GK, et al.Broad specificity of virus specific CD4+T helper cell responses in resolved hepatitis C virus infection[J].J Virol, 2002, 76 (24) :12584-12595.
    [42]韦三华, 尹文, 雷迎峰, 等.HCV多表位基因重组BCG的筛选及其诱导的免疫应答研究[J].中华微生物学和免疫学杂志, 2007, 27 (11) :1041-1045.
    [43]Li D, Xie YW, Jia ZS.Forecasting of hepatitis C virus CTL epitopes and design of multi-epitopes vaccine[J].Zhonghua Gan Zang Bing Za Zhi, 2009, 17 (10) :786-787.
  • 加载中
计量
  • 文章访问数:  3866
  • HTML全文浏览量:  10
  • PDF下载量:  1106
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回